European regulators have now approved a new Alzheimer's drug that they rejected in July. The drug is called Leqembi, brand name for Lecanemab, and is administered via a drip every two weeks. It is a protein that binds to amyloid beta, a substance that forms sticky plaques in the brains of Alzheimer's patients. It is these plaques that are associated with cognitive decline in the disease.
